Table 1.
Baseline SCRPC patient characteristics based on.
| Cases | NLR | P value | PLR | P value | SII | P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| NLR<2.6 | NLR≥2.6 | PLR<144 | PLR≥144 | SII<410 | SII≥410 | |||||
| Age(years) | 0.183 | 0.131 | 0.266 | |||||||
| ≦60 | 56 | 37(59.7%) | 19(46.3%) | 31(62.0%) | 25(47.2%) | 20(62.5%) | 36(50.7%) | |||
| >60 | 47 | 25(40.3%) | 22(53.7%) | 19(38.0%) | 28(52.8%) | 12(37.5%) | 35(49.3%) | |||
| Gender | 0.260 | 0.151 | 0.934 | |||||||
| Male | 67 | 43(69.4%) | 24(58.5%) | 36(72.0%) | 31(58.5%) | 21(65.6%) | 46(64.8%) | |||
| Female | 36 | 19(30.6%) | 17(41.5%) | 14(28.0%) | 22(41.5%) | 11(34.4%) | 25(35.2%) | |||
| Tumor location | <0.001 | 0.110 | 0.007 | |||||||
| Right-sided | 39 | 15(24.2%) | 24(58.5%) | 15(30.0%) | 24(45.3%) | 6(18.8%) | 33(46.5%) | |||
| Left-sided | 64 | 47(75.8%) | 17(41.5%) | 35(70.0%) | 29(54.7%) | 26(81.2%) | 38(53.5%) | |||
| Histological type | 0.068 | 0.347 | 0.250 | |||||||
| Well-differentiated | 59 | 40(64.5%) | 19(46.3%) | 31(62.0%) | 28(52.8%) | 21(65.6%) | 38(53.5%) | |||
| Poor-differentiated | 44 | 22(35.5%) | 22(53.7%) | 19(38.0%) | 25(47.2%) | 11(34.4%) | 33(46.5%) | |||
| CEA level | 0.544 | 0.632 | 0.449 | |||||||
| ≦5ng/ml | 49 | 31(50.0%) | 18(43.9%) | 25(50.0%) | 24(45.3%) | 17(53.1%) | 32(45.1%) | |||
| >5ng/ml | 54 | 31(50.0%) | 23(56.1%) | 25(50.0%) | 29(54.7%) | 15(46.9%) | 39(54.9%) | |||
| Tumor size | 0.192 | 0.554 | 0.159 | |||||||
| ≦5cm | 38 | 26(41.9%) | 12(29.3%) | 17(34.0%) | 21(39.6%) | 15(46.9%) | 23(32.4%) | |||
| >5cm | 65 | 36(58.1%) | 29(70.7%) | 33(66.0%) | 32(60.4%) | 17(53.1%) | 48(67.6%) | |||
| Intraoperative blood transfusion | 0.304 | 0.705 | 0.959 | |||||||
| No | 39 | 21(33.9%) | 18(43.9%) | 18(36.0%) | 21(39.6%) | 12(37.5%) | 27(38.0%) | |||
| Yes | 64 | 41(66.1%) | 23(56.1%) | 32(64.0%) | 32(60.4%) | 20(62.5%) | 44(62.0%) | |||
| T stage | 0.958 | 0.317 | 0.598 | |||||||
| T3 | 38 | 23(37.1%) | 15(36.6%) | 16(32.0%) | 22(41.5%) | 13(40.6%) | 25(35.2%) | |||
| T4 | 65 | 39(62.9%) | 26(63.4%) | 34(68.0%) | 31(58.5%) | 19(59.4%) | 46(64.8%) | |||
| Lymph node metastasis | 0.677 | 0.691 | 0.462 | |||||||
| N0 | 17 | 11(17.7%) | 6(14.6%) | 9(18.0%) | 8(15.1%) | 4(12.5%) | 13(18.3%) | |||
| N+ | 86 | 51(82.3%) | 35(85.4%) | 41(82.0%) | 45(84.9%) | 28(87.5%) | 58(81.7%) | |||
| PM level | 0.001 | <0.001 | 0.001 | |||||||
| limited | 74 | 52(83.9%) | 22(53.7%) | 47(94.0%) | 27(50.9%) | 30(93.8%) | 44(62.0%) | |||
| extended | 29 | 10(16.1%) | 19(46.3%) | 3(6.0%) | 26(49.1%) | 2(6.2%) | 27(38.0%) | |||
| CCR score | 0.001 | <0.001 | 0.002 | |||||||
| CCR0/1 | 68 | 49(79.0%) | 19(46.3%) | 44(88.0%) | 24(45.3%) | 28(87.5%) | 40(56.3%) | |||
| CCR2/3 | 35 | 13(21.0%) | 22(53.7%) | 6(12.0%) | 29(54.7%) | 4(12.5%) | 31(43.7%) | |||